NASDAQ:ZURA - Nasdaq - KYG9TY5A1016 - Common Stock - Currency: USD
1.4
-0.04 (-2.78%)
The current stock price of ZURA is 1.4 USD. In the past month the price decreased by -18.6%. In the past year, price decreased by -61.64%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Zura Bio Ltd. is a clinical-stage biotechnology company that engages in the development of novel medicines for immune disorders. The company is headquartered in La Jolla, California and currently employs 14 full-time employees. The company went IPO on 2021-07-16. The company is developing three assets which have completed Phase I/Ib studies and are Phase II ready. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), ZB-168, and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs. Tibulizumab (ZB-106) is an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of TALTZ (ixekizumab) and tabalumab that neutralizes IL-17A and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain (IL-7R) alpha. Torudokimab (ZB-880) is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.
ZURA BIO LTD
4225 Executive Square, Suite 600
La Jolla CALIFORNIA US
Employees: 15
Company Website: https://zurabio.com/
Investor Relations: https://investors.zurabio.com/
Phone: 18582470520
The current stock price of ZURA is 1.4 USD. The price decreased by -2.78% in the last trading session.
The exchange symbol of ZURA BIO LTD is ZURA and it is listed on the Nasdaq exchange.
ZURA stock is listed on the Nasdaq exchange.
14 analysts have analysed ZURA and the average price target is 14.57 USD. This implies a price increase of 940.81% is expected in the next year compared to the current price of 1.4. Check the ZURA BIO LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ZURA BIO LTD (ZURA) has a market capitalization of 91.41M USD. This makes ZURA a Micro Cap stock.
ZURA BIO LTD (ZURA) currently has 15 employees.
ZURA BIO LTD (ZURA) has a resistance level at 1.56. Check the full technical report for a detailed analysis of ZURA support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ZURA does not pay a dividend.
ZURA BIO LTD (ZURA) will report earnings on 2025-03-27, before the market open.
ZURA BIO LTD (ZURA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.64).
The outstanding short interest for ZURA BIO LTD (ZURA) is 10.5% of its float. Check the ownership tab for more information on the ZURA short interest.
ChartMill assigns a fundamental rating of 3 / 10 to ZURA. ZURA has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months ZURA reported a non-GAAP Earnings per Share(EPS) of -0.64. The EPS increased by 86.21% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -22.54% | ||
ROE | -27.85% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 86% to ZURA. The Buy consensus is the average rating of analysts ratings from 14 analysts.